Entering text into the input field will update the search result below

Summit Therapeutics earn $1M milestone on advancement of ridinilazole

Feb. 06, 2020 10:56 AM ETSummit Therapeutics Inc. (SMMT) StockSMMTBy: Douglas W. House, SA News Editor2 Comments
  • Triggered by achieving the initial enrollment target in trial sites in Latin America, Summit Therapeutics (SMMT -5.2%) has earned a $1M milestone payment from licensee Eurofarma Laboratórios SA related to lead candidate ridinilazole for the treatment of Clostridium difficile (C. diff) infection.
  • The studies are comparing the small molecule antibiotic to standard-of-care vancomycin.

Recommended For You

About SMMT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SMMT--
Summit Therapeutics Inc.